Answers are grounded in this paper and cite their sources.
The acute respiratory distress syndrome (ARDS) is the most serious form of acute respiratory failure in the intensive care unit (ICU), defined by hypoxemia and bilateral opacities on chest radiographic imaging (1). ARDS can represent the end-result of many different insults-such as sepsis, pneumonia, aspiration or pancreatitis-leading to injury of the alveolar epithelial/endothelial interface with resultant permeability edema (2). Epidemiologically, ARDS accounts for up 10% of all ICU admissions and can be diagnosed in up to 23% of mechanically-ventilated patients (2). Severe ARDS carries 30-40% mortality risk, whereas ARDS survivors often suffer from chronic critical illness and longterm neurocognitive deficits (3). Despite advancements in understanding ARDS pathogenesis, no pharmacologic therapy for ARDS has shown efficacy in clinical trials. Thus, invasive mechanical ventilation (IMV) remains the mainstay of ARDS management, with the goals of supporting gas exchange, allowing the respiratory system to "rest", and providing time to treat the underlying pathology.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: